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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not “Is 
Apremilast 30 mg effective in lowering DLQI scores in patients with plaque psoriasis in 16 
weeks of therapy?” 
 
Study Design: Review of three randomized, blind, placebo-controlled clinical trials published 
between the years 2013 and 2016. 
 
Data Sources: All studies were published in peer-reviewed journals that were located using 
PubMed database searches. 
 
Outcome Measured: The DLQI is a 10-item questionnaire that assesses the impact of skin 
disease on health-related quality of life (HRQOL) over the previous week. Scores for each item 
range from 0 (not at all affected) to 3 (very much affected); total scores range from 0 to 30 and 
those >10 represent a very large impact on HRQOL. Patients answered questions regarding their 
physical discomfort and limitations in activities of daily living to psychosocial problems and 
emotional distress caused by the condition. 
 
Results: All studies showed a statistical significance when comparing Apremilast 30mg BID to a 
placebo therapy. DLQI scores were decreased by 6.7 points in the study performed by Paul et al., 
8.3 points with Reich et al. data, and lastly 4.4 points with the Strand et al. study. (P- values for 
all studies <0.05) 
 
Conclusion: According to this EBM review Apremilast 30mg is effective in lowering DLQI 
scores in patients with plaque psoriasis in 16 weeks of therapy. Some studies showed more 
significant decreases in DLQI scores but overall a patient would experience a lower impact of 
skin disease on health-related quality of life.  
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INTRODUCTION 
 Plaque psoriasis is a common chronic inflammatory skin disease that is characterized by 
well-demarcated, erythematous plaques with an overlying silver scale. Pruritis is the main 
symptom patients physically experience and varies from mild to severe.1 Often the disease is 
asymptomatic, but other symptoms may include skin pain or Auspitz sign, which is pin-point 
bleeding when there is minor abrasion to a plaque.1 Plaque psoriasis can affect patients in 
varying degrees of severity; some patients having minimal visible skin lesions while others 
experience a greater percentage of their body surface area being covered. Smaller areas of 
plaques often will coalesce into larger plaques causing increased physical and psychosocial 
discomfort.1 Typically the scalp, lower back, trunk, and extremities are involved but the extensor 
surfaces of joints such as the elbows and knees have an increased predilection.2 Psoriasis may 
not produce physical discomfort for all patients but it is associated with potentially antagonistic 
effects on mental health.2 Patients are at increased risk for depression, anxiety, and suicidality 
when compared with the general population.3 Due to these factors many patients elect to begin 
treatment to increase their overall quality of life and social interactions.  
 Although earlier concepts of the pathogenesis of psoriasis were more focused on 
keratinocyte hyperproliferation, dysregulation of the immune system is now recognized as the 
main cause of the disease.1 The interactions between dendritic cells, T cells, keratinocytes, 
neutrophils, and the cytokines released from immune cells likely contribute to the initiation of 
the cutaneous skin inflammation that is characteristic of psoriasis.4 There is also a genetic factor 
to consider, as approximately 40% of patients with psoriasis have a family history of the disease 
in a first-degree relative.5 Other factors that play a role in the development of psoriasis include 
tobacco and alcohol use, certain medications, infections, and stress.6 
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 Psoriasis is estimated to affect more than 8 million Americans and is one of the most 
common dermatologic and autoimmune conditions treated in the world.2 There are 
approximately 150,000 cases of psoriasis that are diagnosed annually, which contributes to 3 
million visits to healthcare facilities for treatments.7 With treatments often requiring the use of 
biologic agents healthcare costs can be overwhelming to a patient. Biologics as a mainstay for 
treatment can have a mean annual cost of  $53,183.50 for a patient paying out of pocket.8 The 
total burden of psoriasis was recently estimated as $35.2 billion in the United States.9 
 There is currently no cure for psoriasis as it is considered a chronic condition. Therapies 
are targeted at reducing the appearance and size of lesions as well as any associated discomfort. 
Topical therapies are recommended in mild disease states and emphasis on keeping the skin 
moisturized is stressed.2 These therapies include emollients, corticosteroids, Vitamin D analogs, 
calcitriol, tar shampoos, taxarotene, and calcineurin inhibitors.6 When the disease is affecting a 
larger body surface area ultraviolet light therapy may be recommended but can cause a patient to 
be more at risk to develop a skin malignancy.6 In severe cases systemic agents such as 
methotrexate, etanercept, infliximab, and adalimumab may be indicated.6 
 These agents mentioned can help control the extensiveness of psoriasis but can be 
associated with negative side effects, increased medical costs, delayed response to treatment, and 
poor patient satisfaction.10 It is important to have a drug that is designed to directly target the 
formation of psoriasis and also achieve a higher level of patient satisfaction. Apremilast, a 
phosphodiesterase 4 inhibitor, is an oral agent for the treatment of moderate to severe plaque 
psoriasis.10 Phosphodiesterase 4 inhibition reduces production of multiple cytokines involved in 
the pathogenesis of psoriasis.11 This paper assesses the efficacy of Apremilast in improving a 
patient’s quality of life in a 16 week period.  
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OBJECTIVE 
 The objective of this selective evidence based medicine (EBM) review is to determine 
whether or not “Is Apremilast 30 mg effective in lowering DLQI scores in patients with plaque 
psoriasis in 16 weeks of therapy?” 
METHODS 
 In order to be considered and included, the population studied had to be patients 18 years 
of age or older clinically diagnosed with chronic plaque psoriasis for 6 months or longer. The 
study had to be a randomized controlled trial that included a treatment group taking Apremilast 
30mg orally twice day (BID) and the control group receiving a placebo. Outcomes were 
measured using Dermatology Life Quality Index (DLQI) self-report questionnaire scores and 
their mean change from baseline at 16 weeks of treatment.  
 To find appropriate articles, keywords that were used included: “Apremilast”; “Plaque 
Psoriasis”. Articles had to be in the English language and published in peer-reviewed journals. 
The author used the listed keywords to search online PubMed databases that addressed the 
objective of this review and used a patient centered outcome to measure the overall effect on a 
patient’s quality of life. For an article to be considered it had to be a randomized, blinded, 
placebo-controlled trial using Apremilast as a treatment option. These articles had to be 
published within the last 10 years to ensure all data was up to date. If an article included patients 
under the age of 18 it would be rejected and excluded from the data. The specific demographics 
and characteristics for each individual study can be found in Table 1. 
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TABLE 1: DEMOGRAPHICS & CHARACTERISTICS OF INCLUDED STUDIES  
Study Type # 
Pts.  
Age 
(years) 
Inclusion 
criteria 
Exclusion Criteria W/D Interventions 
Paul et 
al.11 
(2015) 
RCT, 
double 
blinded, 
placebo 
controlled 
411 45.3 
±13.1 
Adults ³18 
years of age 
were eligible if 
diagnosed with 
chronic plaque 
psoriasis for ³ 
12 months.  
Patients had 
moderate-to-
severe plaque 
psoriasis, 
defined as 
Psoriasis Area 
and Severity 
Index (PASI) 
score ³ 12.  
Clinically significant 
cardiac, endocrinological, 
pulmonary, neurological, 
psychiatric, hepatic, renal, 
hematological or 
immunological disease; 
other major uncontrolled 
disease. 
Prolonged sun or 
ultraviolet exposure. 
Biologic therapy within 
12-24 weeks, conventional 
systemic treatments within 
4 weeks, topical treatments 
for psoriasis within 2 
weeks. 
 
60 Regimen of 
Apremilast 
30mg orally 
BID 
Reich et 
al.12 
(2017) 
RCT, 
double-
blind, 
placebo-
controlled 
study 
 
167 46.0 
±13.6 
Adults aged 
≥18 years were 
eligible if they 
had chronic 
plaque 
psoriasis for 
≥12 months 
(PASI score 
≥12). 
No prior 
exposure to a 
biologic 
therapy for 
psoriasis or 
psoriatic 
arthritis. 
 
Patients with prior failure 
of >3 systemic agents for 
treatment of psoriasis 
History of known 
demyelinating diseases 
such as multiple sclerosis 
or optic neuritis or history 
of or concurrent congestive 
heart failure, including 
medically controlled, 
asymptomatic congestive 
heart failure; other 
clinically significant or 
major uncontrolled disease 
 
15 Regimen of 
Apremilast 
30mg orally 
BID  
 
Strand 
et al.10 
(2013) 
RCT, 
blinded, 
placebo-
controlled 
176 44.1 ± 
14.7 
Adults ³18 
years of age 
with stable, 
chronic, 
moderate to 
severe plaque 
psoriasis (PASI 
³12 for ³ 6 
months) who 
were 
candidates for 
therapy. 
Concomitant phototherapy 
and use of systemic 
biologic agents, use of 
topical agents except for 
Eucerin cream; low 
potency corticosteroids for 
facial, axillary, and groin 
lesions; and coal tar 
shampoo or salicylic acid 
preparations for scalp 
lesions.  
LOCF 
used 
Regimen of 
Apremilast 
30mg orally 
BID 
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OUTCOMES MEASURED 
 The outcomes were measured using the Dermatology Life Quality Index (DLQI) which is 
a 10-item questionnaire that assesses the impact of skin disease on health-related quality of life 
(HRQOL) over the previous week. Questions range from physical discomfort and limitations in 
activities of daily living to psychosocial problems and emotional distress experienced by the 
patient. Scores for each item range from 0 (not at all affected) to 3 (very much affected); total 
scores range from 0 to 30 and those >10 represent a very large impact on HRQOL. 10,11,12 The 
mean change from the baseline score at the start of therapy was collected at week 16 as well as 
other time intervals.  
RESULTS 
 The three studies selected compared the effectiveness of Apremilast 30mg twice a day to 
a placebo when treating adults with chronic plaque psoriasis. All studies used the DLQI 
questionnaire to evaluate if the treatment given caused an overall improvement and mean change 
from baseline over a set of timed intervals (Table 2). Each study also included a P-value to show 
the statistical significance of Apremilast versus a placebo (Table 3). 
TABLE 2. DLQI MEAN CHANGE FROM BASELINE IN 16 WEEKS 
 Study 1 Study 2 Study 3 
DLQI Mean Change 
from Baseline ± SD 
with Apremilast 30mg 
-6.7 -8.3±7.7 
 
-4.4 ±5.1  
 
DLQI Mean Change 
from Baseline ± SD 
with Placebo 
-2.8 -3.8±5.6 −1.9 ± 5.2 
 
TABLE 3. STATISTICAL SIGNIFICANCE OF INTERVENTION VS. PLACEBO 
 Study 1 Study 2 Study 3 
P- Value P<0.001 P<0.0001 P£0.005   
*Statistical significance was considered to be a p-value <0.05 
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 The first study by Paul et al., was a phase III, randomized, double-blind, placebo-
controlled study that monitored the efficacy and safety of Apremilast 30mg twice a day over 52 
weeks compared to a placebo. The study included three time periods, week 16, week 32, and 
week 52, where patient data was collected. It specifically excluded patients who had used 
biologics within 12-24 weeks, conventional systemic treatments within 4 weeks, topical 
treatments for psoriasis within 2 weeks, and anyone with prolonged sun or ultraviolet exposure. 
Such factors could cause a patient to experience a decrease in DLQI scores that are unrelated to 
Apremilast treatment. Additional exclusion and inclusion criteria can be seen in Table 1. 
Apremilast showed significant improvement at week 16 of the study with 70.8% of the 
population that had a DLQI score >5 decreasing their DLQI score by 5 or more points (Table 4). 
The mean change from baseline reported by the study showed overall a 6.7 point decrease in 
DLQI scores in patients treated with Apremilast 30mg twice a day (Table 2). Within the 16-week 
period 60 of 411 patients discontinued treatment due to multiple factors (Table 5). Missing data 
was handled with last-observation-carried-forward (LOCF) methodology.  
 TABLE 4. DLQI RESPONSE (DECREASE OF ³ 5 POINTS) IN 16 WEEKS 
 Placebo (%) Apremilast 30 mg (%) P-Value  
Study 1 42.9 70.8 <0.001 
Study 2 41.7 65.1 0.0032 
 
TABLE 5. PATIENTS COMPLIANCE WITH INTERVENTION IN STUDY 1 
Discontinued 
due to:  
Adverse 
event 
Lack of 
efficacy 
Withdrawn 
consent  
Lost to 
follow-
up 
Protocol 
violation 
Non- 
Compliant 
Other  Total 
Placebo 
Group 
(n=137) 
8 2 7 6 1 0 1 25 
Apremilast 
30mg BID 
(N=274) 
12 3 9 6 2 1 2 35 
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 The second study by Reich et al., was a phase IIIb, randomized, double blind, placebo-
controlled study that monitored the efficacy and safety of Apremilast 30mg twice a day and 
Etanercept 50mg once daily subcutaneous injection compared to a placebo. The trial included a 
placebo-controlled phase through 16 weeks with the 3 separate test groups as well as an 
Apremilast extension phase through 52 weeks. It specifically included patients who had 
previously had inadequate response, intolerance or contraindication to ≥1 conventional systemic 
agents for treatment of psoriasis, were candidates for phototherapy or systemic therapy, and had 
no prior exposure to a biologic therapy for psoriasis or psoriatic arthritis. Additional criteria can 
be seen in Table 1.  Apremilast again showed significant improvement at week 16 of the study 
with 65.1% of the population that had a DLQI score >5 decreasing their DLQI score by 5 or 
more points (Table 4). The mean change from baseline reported by the study showed overall a 
8.3 point decrease in DLQI scores in patients treated with Apremilast 30mg twice a day (Table 
2). Within the 16-week period 15 of 167 patients discontinued treatment due to multiple factors 
(Table 6). Last observation carried forward (LOCF) methodology was used to impute missing 
efficacy measurements. 
TABLE 6. PATIENTS COMPLIANCE WITH INTERVENTION IN STUDY 1 
Discontinued due to:  Adverse 
event 
Lack of 
efficacy 
Withdrawn 
consent  
Other  Total 
Placebo Group 
(n=84) 
2 4 1 2 9 
Apremilast 30mg BID 
(N=83) 
2 3 0 1 6 
 
 The third study by Strand et al., was a phase IIb, randomized, controlled study that 
looked at improvements in patient reported outcomes with Apremilast therapy. The study had 
four groups that were monitored through 16 weeks. Patients were randomly placed in groups 
receiving one of the following; placebo, Apremilast 10mg BID, Apremilast 20mg BID, 
Apremilast 30mg BID. All inclusion and exclusion criteria of the study can be found in Table 1. 
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The mean change from baseline reported by the study showed overall a 4.4 point decrease in 
DLQI scores in patients treated with Apremilast 30mg BID (Table 2). This particular study did 
not give data concerning the number of patients who did not complete a full 16 weeks of therapy. 
Last observation carried forward (LOCF) methodology was used to impute missing data. 
DISCUSSION 
 The goal of this study was to determine if Apremilast 30mg could effectively lower 
DLQI scores in patients in 16 weeks of therapy. With the analyzation of the three studies 30mg 
Apremilast proved to decrease DLQI scores within the 16-week time frame.  
 Apremilast was approved by the FDA for treatment of patients with moderate to severe 
plaque psoriasis who are candidates for phototherapy or systemic therapy as well as psoriatic 
arthritis in March of 2014.13 Apremilast is also recognized by the brand name Otezla and is an 
oral medication that can be taken without regards to food.14 Contraindications are not listed on 
US labels but on Canadian labeling it is contraindicated in pregnancy and breast feeding.13 
Common side effects listed include GI upset such as diarrhea, nausea, and vomiting.13 
Neuropsychiatric effects include increased risk of depression and suicidal ideation.13 Weight loss 
may also be a concerning side effect. Dosage reduction is also recommended in patients with a 
CrCl <30 mL/min.13 With the listed contraindications and side effects a significant portion of 
patients with psoriasis may not find Apremilast to be worth the shown treatment efficacy. 
Especially concerning is that a patient already suffering from depression due to their skin 
appearance may be put at an increased risk of harming themselves. It is important to monitor a 
patient’s weight, renal function, and mood fluctuations regularly during therapy.  
 Cost and availability to patients is one of the largest draw backs. There is no generic 
available to patients in the US and tablets cost approximately $65.66 per tablet.13 Coverage by 
insurances varies and many require failed biologic therapy to get approval for the medication.15 
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Currently Otezla offers a zero dollar copay for select patient populations and healthcare 
providers may also fill out forms stating medical necessity to obtain coverage for their patients.14 
 There are multiple limitations noted throughout the studies. The use of LOCF assumes 
that the missing data after patient's withdrawal are the same as the last value observed for that 
patient. The consequence of this particular assumption is that it imputes data without giving 
subject variability and it also alters the true sample size. All three studies used this methodology 
when dealing with patients who discontinued therapy. Some studies allowed low-potency topical 
corticosteroids as background therapy for face, axilla and groin psoriasis lesions, coal tar 
shampoo and/or salicylic acid preparations for scalp lesions and non-medicated emollients for 
body lesions were also permitted. Patients also were not prohibited from receiving live 
vaccinations during some of the studies. There were also no protocol requirements to stop the 
study medication for an infection in all studies. Infection side effects could cause DLQI scores to 
fluctuate unrelated to study treatments.  All of these listed factors could affect the validity of 
results.  
CONCLUSION 
 According to this EBM review Apremilast 30mg is effective in lowering DLQI scores in 
patients with plaque psoriasis in 16 weeks of therapy. Some studies showed more significant 
decreases in DLQI scores, but overall a patient would experience a lower impact of skin disease 
on health-related quality of life. The three studies used tested large populations with patient 
demographics being very closely matched within comparison groups. These factors helped to 
increase the validity of the results. 
 For future research to improve from past studies, there should be consideration that social 
interactions are at their peak during teenage years to young adulthood. The mean age studied was 
approximately 45 years of age between the three studies. Additional studies should look to 
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include a younger database of patients. Also, with first line treatment of plaque psoriasis being 
topical therapies such as emollients, corticosteroids, and Vitamin D analogs, application would 
typically be twice a day if using monotherapy. It would be important to compare compliance in 
patients to see if an oral medication or topical medication, taken twice daily, is preferred by a 
patient. 
 To face the large cost for the drug in today’s market it is important that future research is 
aimed to directly compare other therapies such as biologics to Apremilast. This research should 
aim to show that Apremilast is equally effective as well as safer for patient usage. Such future 
research is warranted to help Apremilast gain more formulary coverage for patients with 
commercial insurance.   
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